Current Standards of Systemic Therapies in Advanced Hepatocellular Cancer: A Review


Authored by Piyush Vyas

Sorafenib a multikinase inhibitor is the only approved systemic therapy in the treatment of advanced hepatocellular cancer. No other targeted therapy have proved to be better, a lot of phase 3 trials with many targeted have shown no significant or clinically relevant activity. After SHARP trial no other trial with any other targeted therapy has shown any significant improvement in the treatment of hepatocellular cancer. EACH trial, a phase 3 randomized trial conducted on Asian patients proved better RR and PFS of FOLFOX4 regimen when compared to doxorubicin, showed efficacy and safety of FOLFOX4 protocol. In the light of so many negative phase 3 trials with targeted therapies, it seems only sorafenib still can be considered a standard therapy in advanced HCC.



Comments

Post a Comment

Popular posts from this blog

Drivers of Precision Medicine: Liquid Biopsy and Next-Generation Sequencing

Image
Cancer Therapy & Oncology- Juniper Publishers                                                      Abbreviations cfDNA: Cell-Free DNA; NGS: Next-Generation Sequencing; WGS: Whole Genome Sequencing; WES: Whole Exome Sequencing; GH: Guardant Health; CT: Circulogene Theranostics Editorial Targeted therapy specifically aims at tumor genetic alterations s the hallmark of precision medicine. Companion diagnostic testing utilized to determine the presence or absence of certain oncogenic mutations prior to targeted treatment under the current medical guidelines will enable improved clinical outcome, and thus serves as a vital component for precision medicine. Standard clinical practice to assess genetic mutations in cancer patients has historically been through direct sampling of tumor tissue with biopsy or surgical resection. Unfortunately, tissue biopsy is...
Read more

Recent Advance in Diagnosis, Pathogenesis and Risk Stratification of Essential Thrombocythemia

Image
Cancer Therapy & Oncology- Juniper Publishers                                               Abstract In the 2016 version of WHO classification, bone marrow morphology is critical in the distinction between ET and pre-PMF. Reticulin-fiber grading becomes central: grade 1 or less is needed for ET. Furthermore,  CALR  assessment must be performed in all ET patients without  JAK2  mutation. Some prognostic implications have been described for  CALR  mutations, i.e., a lower risk of thrombosis in ET. Abbreviations:  MPN: Myelo Proliferative Neoplasm; WHO: World Health Organization; JAK: Janus kinase; CALR: Calreticulin; bp: base pair; MPL: Myelo Proliferative Leukemia virus oncogene; TPO: Thrombo Protein; RARS-T: Refractory Anemia with Ring Sideroblasts associated with marked Thrombocytosis; PMF: Primary Myelo Fibrosis; IPSET: The Internati...
Read more

A Young Woman with Coomb's Positive Severe Haemolytic Anaemia and Hodgkin Lymphoma that Responded Completely to Rituximab: A Case Report

Image
  Cancer Therapy & Oncology- Juniper Publishers                                                      Abstract Introduction Lymphoma has been historically divided into a Hodgkin and Non-Hodgkin variety. There are reported cases of Hemolytic Anemia in Non- Hodgkin Lymphoma but Hodgkin Lymphoma very rarely also present with Hemolytic Anemias. Case presentation A 27-year-old African woman presented with chronic fatigue, dyspnoea, jaundice and Splenomegalie. Her blood work revealed severe anaemia (haemoglobin, 4.9 g/dl) with biochemical evidence of haemolysis. A direct Coomb's test was reported positive. A biopsy of the lymph nodes in the neck confirmed Hodgkin Lymphoma. Initial therapy consisted of intravenous methyl prednisolone and switched over to Oral Prednisolone. However, the patient came back with raised sugar levels and there was no clinical...
Read more